Details for New Drug Application (NDA): 018655
✉ Email this page to a colleague
NDA 018655 describes NORPACE CR, which is a drug marketed by Pfizer and is included in one NDA. Additional details are available on the NORPACE CR profile page.
The generic ingredient in NORPACE CR is disopyramide phosphate. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the disopyramide phosphate profile page.
The generic ingredient in NORPACE CR is disopyramide phosphate. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the disopyramide phosphate profile page.
Summary for 018655
| Tradename: | NORPACE CR |
| Applicant: | Pfizer |
| Ingredient: | disopyramide phosphate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 018655
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | EQ 100MG BASE | ||||
| Approval Date: | Jul 20, 1982 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | EQ 150MG BASE | ||||
| Approval Date: | Jul 20, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
